Corporate Overview August 2021 NASDAQ: AADI www.aadibio.com Aadi Bioscience Inc., Pacific Palisades, CA 90272, USA 1 Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this presentation

Aadi Bioscience Inc., Pacific Palisades, CA 90272, USA 1Exhibit 99.1 Corporate Overview August 2021 NASDAQ: AADI www.aadibio.com Aadi Bioscience Inc., Pacific Palisades, CA 90272, USA 1

Cautionary Note Regarding Forward-Looking Statements Certain

statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation

Act of 1995, known as the PSLRA. These include statements regarding management's intention, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking

statement can be guaranteed, and actual results may differ materially from those projected. Aadi Bioscience, Inc. ("Aadi") undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information,

future events or otherwise, except to the extent required by law. We use words such as "anticipates," "believes," "plans," "expects," "projects," "intends," "may,"

"will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and similar expressions to identify these forward-looking

statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from

those expressed or implied in the statements due to a number of factors, including, but not limited to, risks related to the sufficiency Aadi's cash balance to fund operations; Aadi's plans to develop and potentially commercialize its

product candidates, including FYARRO (nab-sirolimus, ABI- 009); the timing of initiation of Aadi's planned clinical trials; the timing of the availability of data from Aadi's clinical trials; the timing of regulatory review of

Aadi's new drug application for FYARRO; Aadi's plans to research, develop and commercialize its current and future product candidates; Aadi's ability to successfully enter into collaborations, and to fulfill its obligations under

any such collaboration agreements; the clinical utility, potential benefits and market acceptance of FYARRO and any other of Aadi's product candidates; Aadi's commercialization, marketing and manufacturing capabilities and strategy;

Aadi's ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to Aadi's competitors and our its industry; the impact of government laws and regulations;

Aadi's ability to protect its intellectual property position; the impact of the COVID-19 outbreak on Aadi's operations, the biotechnology industry and the economy generally and Aadi's estimates regarding future revenue, expenses,

capital requirements and need for additional financing. These risks are described in detail under the caption "Risk Factors" in the definitive proxy statement filed with the Securities and Exchange Commission (the

"SEC") on July 8, 2021 in connection with the Aerpio reverse merger with Aadi. Additional risks and uncertainties are identified and discussed in the "Risk Factors" section of Aerpio's Quarterly Report on Form 10-Q,

filed with the SEC on August 11, 2021, and other documents filed from time to time with the SEC, including Aadi's Quarterly Report on Form 10-Q to be filed with the SEC for the quarter-ended September 30, 2021. Forward-looking statements

included in this presentation are based on information available to Aadi as of the date of this presentation. Aadi undertakes any obligation to such forward-looking statements to reflect events or circumstances after the date of this presentation.

2Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and

Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as the PSLRA. These include statements regarding management's intention, plans, beliefs, expectations or forecasts for the future, and, therefore, you

are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Aadi Bioscience, Inc. ("Aadi") undertakes no obligation to publicly update

any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as "anticipates," "believes," "plans,"

"expects," "projects," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue,"

"guidance," and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and

involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, risks related to the sufficiency Aadi's cash

balance to fund operations; Aadi's plans to develop and potentially commercialize its product candidates, including FYARRO (nab-sirolimus, ABI- 009); the timing of initiation of Aadi's planned clinical trials; the timing of the

availability of data from Aadi's clinical trials; the timing of regulatory review of Aadi's new drug application for FYARRO; Aadi's plans to research, develop and commercialize its current and future product candidates;

Aadi's ability to successfully enter into collaborations, and to fulfill its obligations under any such collaboration agreements; the clinical utility, potential benefits and market acceptance of FYARRO and any other of Aadi's product

candidates; Aadi's commercialization, marketing and manufacturing capabilities and strategy; Aadi's ability to identify additional products or product candidates with significant commercial potential; developments and projections

relating to Aadi's competitors and our its industry; the impact of government laws and regulations; Aadi's ability to protect its intellectual property position; the impact of the COVID-19 outbreak on Aadi's operations, the

biotechnology industry and the economy generally and Aadi's estimates regarding future revenue, expenses, capital requirements and need for additional financing. These risks are described in detail under the caption "Risk

Factors" in the definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on July 8, 2021 in connection with the Aerpio reverse merger with Aadi. Additional risks and uncertainties are identified and

discussed in the "Risk Factors" section of Aerpio's Quarterly Report on Form 10-Q, filed with the SEC on August 11, 2021, and other documents filed from time to time with the SEC, including Aadi's Quarterly Report on Form

10-Q to be filed with the SEC for the quarter-ended September 30, 2021. Forward-looking statements included in this presentation are based on information available to Aadi as of the date of this presentation. Aadi undertakes any obligation to such

forward-looking statements to reflect events or circumstances after the date of this presentation. 2

AADI BIOSCIENCE, INC: INTRODUCTION Aadi-Aerpio Merger Closed

Aadi Bioscience, Inc. trading on Nasdaq under "AADI" following merger with Aerpio Pharmaceuticals, Inc. The company will focus on advancing Aadi's lead product candidate, FYARRO (nab-sirolimus, ABI-009)

Concurrent PIPE financing of $155 million led by Acuta and KVP and including Avoro, Venrock, BVF, Vivo, Alta, Rock Springs, RTW, Acorn, and Serrado Cash balance post-closing of approximately $170 million with projected runway into 2024

Total shares outstanding: 20.8 million 3AADI BIOSCIENCE, INC: INTRODUCTION Aadi-Aerpio Merger Closed Aadi Bioscience, Inc. trading on Nasdaq under "AADI" following merger with Aerpio Pharmaceuticals, Inc. The

company will focus on advancing Aadi's lead product candidate, FYARRO (nab-sirolimus, ABI-009) Concurrent PIPE financing of $155 million led by Acuta and KVP and including Avoro, Venrock, BVF, Vivo, Alta, Rock Springs, RTW,

Acorn, and Serrado Cash balance post-closing of approximately $170 million with projected runway into 2024 Total shares outstanding: 20.8 million 3

Aadi Board of Directors CEO Board of Directors Neil Desai, PhD Behzad

Aghazadeh, PhD Caley Castelein, MD Anupam Dalal, MD Karin Hehenberger, MD, PhD Richard Maroun Founder, CEO and President Chairman Former Sr VP, Global Managing Partner & Managing Director, KVP Chief Investment

Officer & Founder & CEO, Lyfebulb Partner, General Counsel, R&D at Abraxis Portfolio Manager, Capital and Kearny Portfolio Manager, Acuta Frazier Healthcare 20+ years experience in Bioscience Avoro Capital Venture

Partners Capital Partners the life sciences sector Former Vice President, 25+ years biopharma 20+ years of healthcare 18+ years of healthcare 20+ years biopharma Former executive at Strategic

Platforms, industry experience experience as a principal experience as a principal industry experience Eyetech Pharmaceuticals Celgene investor investor Former Executive & Coronado BioSciences Former SVP and General

Inventor of the nab Chairman of Board Member at Former Managing Counsel, Aptalis Previously held strategic technology (ABRAXANE Immunomedics (acquired ViewRay, Inc. (VRAY), Director at Kearny Pharmaceuticals management roles

at and ABI-009) by Gilead in 2020) Newbridge Venture Partners and Johnson & Johnson, Previously held senior Pharmaceuticals, and Principal at Flagship Led development of Extensive scientific JDRF, and McKinsey and

executive roles at APP Aerpio Pharmaceuticals Pioneering ABRAXANE research and multibillion dollar Pharmaceuticals, Abraxis management consulting Board Member at Aerpio investment funds Bioscience, and American 25+ years in R&D

experience Pharmaceuticals Bioscience Inc. 4Aadi Board of Directors CEO Board of Directors Neil Desai, PhD Behzad Aghazadeh, PhD Caley Castelein, MD Anupam Dalal, MD Karin Hehenberger, MD, PhD Richard Maroun Founder, CEO and President Chairman

Former Sr VP, Global Managing Partner & Managing Director, KVP Chief Investment Officer & Founder & CEO, Lyfebulb Partner, General Counsel, R&D at Abraxis Portfolio Manager, Capital and

Kearny Portfolio Manager, Acuta Frazier Healthcare 20+ years experience in Bioscience Avoro Capital Venture Partners Capital Partners the life sciences sector Former Vice President, 25+ years biopharma 20+ years of

healthcare 18+ years of healthcare 20+ years biopharma Former executive at Strategic Platforms, industry experience experience as a principal experience as a principal industry experience Eyetech Pharmaceuticals Celgene

investor investor Former Executive & Coronado BioSciences Former SVP and General Inventor of the nab Chairman of Board Member at Former Managing Counsel, Aptalis Previously held strategic

technology (ABRAXANE Immunomedics (acquired ViewRay, Inc. (VRAY), Director at Kearny Pharmaceuticals management roles at and ABI-009) by Gilead in 2020) Newbridge Venture Partners and Johnson & Johnson, Previously held senior

Pharmaceuticals, and Principal at Flagship Led development of Extensive scientific JDRF, and McKinsey and executive roles at APP Aerpio Pharmaceuticals Pioneering ABRAXANE research and multibillion dollar Pharmaceuticals, Abraxis

management consulting Board Member at Aerpio investment funds Bioscience, and American 25+ years in R&D experience Pharmaceuticals Bioscience Inc. 4

Aadi Bioscience is a late-stage, precision oncology company

re-engineering mTOR inhibition FYARRO (nab-sirolimus, ABI-009) is a nanoparticle albumin-bound form of sirolimus Similar technology platform to ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (Bristol

Myers Squibb Corporation) Albumin-based technology results in higher intratumoral concentrations, increased target suppression, and improved tumor growth inhibition and survival in animal models compared to other mTOR inhibitors Lead

indication PEComa, a rare tumor with high frequency of TSC1 and TSC2 alterations Endpoints met in registrational trial in patients with PEComa Breakthrough therapy designation granted NDA accepted for filing with Priority

Review and November 26, 2021 PDUFA target action date Commercial preparations underway to support U.S. launch Tumor-agnostic opportunity in TSC1 and TSC2 alterations Strong mechanistic rationale; potential for validation with PEComa

approval 1 Preliminary EAP data presented at ASCO 2021 supportive of tumor-agnostic strategy 5 5 EAP = Expanded Access Program 1) MA Dickson. ASCO. 2021. Abstract # 3111Aadi Bioscience is a late-stage, precision oncology company

re-engineering mTOR inhibition FYARRO (nab-sirolimus, ABI-009) is a nanoparticle albumin-bound form of sirolimus Similar technology platform to ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (Bristol

Myers Squibb Corporation) Albumin-based technology results in higher intratumoral concentrations, increased target suppression, and improved tumor growth inhibition and survival in animal models compared to other mTOR inhibitors Lead

indication PEComa, a rare tumor with high frequency of TSC1 and TSC2 alterations Endpoints met in registrational trial in patients with PEComa Breakthrough therapy designation granted NDA accepted for filing with Priority

Review and November 26, 2021 PDUFA target action date Commercial preparations underway to support U.S. launch Tumor-agnostic opportunity in TSC1 and TSC2 alterations Strong mechanistic rationale; potential for validation with PEComa

approval 1 Preliminary EAP data presented at ASCO 2021 supportive of tumor-agnostic strategy 5 5 EAP = Expanded Access Program 1) MA Dickson. ASCO. 2021. Abstract # 3111

ABI-009 Advanced Oncology Pipeline Indication Phase 1b Phase 2

Registrational Upcoming Milestones Potential first FDA approval for PEComa, histology with high November 26, 2021 Single Agent Advanced Malignant PEComa PDUFA frequency of TSC1 and TSC2 alterations Single Agent Pan-Tumor TSC1 Inactivating

Alterations File IND for tumor-agnostic pivotal study with independent arms for TSC1 or TSC2 inactivating mutations; trial to be initiated by year end 2021 Single Agent Pan-Tumor TSC2 Inactivating Alterations Expanded Access Program Provide access

to ABI-009 pre-approval to patients with PEComa or Single Agent (Solid Tumors mTOR Pathway solid tumors with mTOR pathway mutations Alterations) Dose Finding Combination Studies Continue ongoing combination partner trials and initiate new

trials with adjacent pathway combinations that may be synergistic (Multiple) Undisclosed indication: single agent Expand into a sub-population with strong mTOR mechanistic rationale expansion Ongoing To be initiated Planned/ initial

ABI-009: Leveraging Albumin to Improve mTOR Inhibition 7

Nanoparticle Albumin-Bound (nab) Technology Nab Platform (nab

paclitaxel) paclitaxel sirolimus Artist impression Albumin Artist impression Albumin 1 1 2 Proprietary, complex, multistep Superior efficacy , safety , and PK/PD Licensed from Celgene in 2014 manufacturing process with vs.

standard formulation paclitaxel Larger PK/PD differences vs. reference trade secrets 4 Approved for breast cancer, NSCLC, drug than ABRAXANE 1 and pancreatic cancer "nab" process adapted for sirolimus

Commercially successful with >$1B in WW patent portfolio with issued patents 3 annual sales providing coverage to 2036 ABRAXANE is a registered trademark of Celgene Corporation 8 1) ABRAXANE prescribing information 2) N Desai et

al., Clin Cancer Res. 2006;12(4):1317-1324. 3) Evaluate Pharma. Accessed April 2021 4) see following slides for detailsNanoparticle Albumin-Bound (nab) Technology Nab Platform (nab paclitaxel) paclitaxel sirolimus Artist impression Albumin Artist

impression Albumin 1 1 2 Proprietary, complex, multistep Superior efficacy , safety , and PK/PD Licensed from Celgene in 2014 manufacturing process with vs. standard formulation paclitaxel Larger PK/PD differences vs.

reference trade secrets 4 Approved for breast cancer, NSCLC, drug than ABRAXANE 1 and pancreatic cancer "nab" process adapted for sirolimus Commercially successful with >$1B in WW patent portfolio with

issued patents 3 annual sales providing coverage to 2036 ABRAXANE is a registered trademark of Celgene Corporation 8 1) ABRAXANE prescribing information 2) N Desai et al., Clin Cancer Res. 2006;12(4):1317-1324. 3) Evaluate Pharma. Accessed

April 2021 4) see following slides for details

ABI-009 Targets mTOR, a Key Signaling Pathway in Cancer PI3K/Akt/mTOR

pathway Growth Insulin Factors PI3K Ras PTEN Raf Akt MEK ERK Frequently TSC1/ mutated in cancer TSC2 and/or validated target Rheb mTOR complex 1 mTOR ABI-009 (mTORC1) Raptor S6K 4EBP1 9ABI-009 Targets mTOR, a Key Signaling Pathway in Cancer

PI3K/Akt/mTOR pathway Growth Insulin Factors PI3K Ras PTEN Raf Akt MEK ERK Frequently TSC1/ mutated in cancer TSC2 and/or validated target Rheb mTOR complex 1 mTOR ABI-009 (mTORC1) Raptor S6K 4EBP1 9

ABI-009 Achieves Larger PK/PD Difference vs Reference Drug Preclinical

Tumor Exposure (AUC) Clinical Whole Blood AUC Fold Change vs. Reference Drug at Fold Change vs. Reference Drug at Equal Dose (Xenograft Model) Clinical Dose (Clinical Data) 50 18 16 43 45 16 40 14 35 12 30 10 25 8 20 6 15 4 10 1.2 2 5 1.3 0 0 1 2 3

4,5 Abraxane IV / paclitaxel IV ABI-009 IV / sirolimus PO Abraxane IV / paclitaxel IV ABI-009 IV / sirolimus PO* 2 2 2 Total dose = Total dose = 260 mg/m 175 mg/m 100 mg/m 5-6 mg/day 100 mg/kg over 5d 15 mg/kg over 7 days Note: FDA approved dosing

& admin schedule used for Abraxane, paclitaxel, and sirolimus. PEComa registrational trial dose used for ABI-009 * Indirect comparison of ABI-009 clinical data to published clinical data for sirolimus 1) N Desai et al., Clin Cancer Res.

2006;12(4):1317-1324. 5) Sirolimus: Mean of the following two sources: 2) S Hou et al. AACR 2019. (a) A Jimeno et al., J Clin Oncol. 2008;26(25):4172-4179. and 3) A Sparreboom et al., Clin Cancer Res. 2006;11(11):4136-4143. (b) I Garrido-Laguna et

al., Br J Cancer. 2010;103(5):649-655. 10 4) ABI-009: AM Gonzalez-Angulo et al., Clin Cancer Res 2013;19:5474-5484.ABI-009 Achieves Larger PK/PD Difference vs Reference Drug Preclinical Tumor Exposure (AUC) Clinical Whole Blood AUC Fold Change vs.

Reference Drug at Fold Change vs. Reference Drug at Equal Dose (Xenograft Model) Clinical Dose (Clinical Data) 50 18 16 43 45 16 40 14 35 12 30 10 25 8 20 6 15 4 10 1.2 2 5 1.3 0 0 1 2 3 4,5 Abraxane IV / paclitaxel IV ABI-009 IV / sirolimus PO

Abraxane IV / paclitaxel IV ABI-009 IV / sirolimus PO* 2 2 2 Total dose = Total dose = 260 mg/m 175 mg/m 100 mg/m 5-6 mg/day 100 mg/kg over 5d 15 mg/kg over 7 days Note: FDA approved dosing & admin schedule used for Abraxane, paclitaxel, and

sirolimus. PEComa registrational trial dose used for ABI-009 * Indirect comparison of ABI-009 clinical data to published clinical data for sirolimus 1) N Desai et al., Clin Cancer Res. 2006;12(4):1317-1324. 5) Sirolimus: Mean of the following two

sources: 2) S Hou et al. AACR 2019. (a) A Jimeno et al., J Clin Oncol. 2008;26(25):4172-4179. and 3) A Sparreboom et al., Clin Cancer Res. 2006;11(11):4136-4143. (b) I Garrido-Laguna et al., Br J Cancer. 2010;103(5):649-655. 10 4) ABI-009: AM

Gonzalez-Angulo et al., Clin Cancer Res 2013;19:5474-5484.

Role of Albumin in Tumor Targeting Albumin accumulation in tumors

Labeled albumin can be used intraoperatively to established in multiple preclinical models guide surgical resection of tumors in humans Accumulation of the evans blue albumin complex 5-Amino Fluorescein labelled Albumin administered IV

(0.5-1 mg/kg) in 13 patients, 0.5-4 in subcutaneously growing sarcoma 180 tumors days before surgery over 72 h Tumor fluorescence was bright in 11 patients (84%), resulting in complete resection in 9 patients (69%) Y Shahzad et al., Curr